TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25204013
Drug: Magnesium lactate
Normalized name: Magnesium lactate
DrugBank: Magnesium lactate (DB14515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium lactate (360 mg elemental magnesium)
Study: 22828734
Drug: Control (iso-energetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (iso-energetic and iso-proteinaceous supplement)
Study: 20625131
Drug: Pyridoxine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (200 mg/d)
Study: 12439645
Drug: Ephedrine and
Normalized name: Ephedrine and guaifenesin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine and caffeine (20/200 mg, three times daily) for 4 weeks
Study: 9101609
Drug: Moderate renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate renal function deficit (CrCl 25 to 60 mL/min)
Study: 9101609
Drug: Mild renal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild renal function deficit (CrCl >= 60 mL/min)
Study: 2779901
Drug: Antibiotic regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic regimens in the trial
Study: 1105628
Drug: Probenecid administration
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probenecid administration
Study: 27562843
Drug: H1/H2-receptor blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1/H2-receptor blockers
Study: 25465711
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (1 ml methylprednisolone acetate)
Study: 25465711
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (1 ml methylprednisolone acetate + 15-day delayed 2 ml saline 0.9 %)
Study: 25465711
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (1 ml methylprednisolone acetate + 15-day delayed 2 ml low molecular weight hyaluronic acid)
Study: 17378196
Drug: Electroacupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture combined with point-injection
Study: 11346005
Drug: Standard CSU‐13B/P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CSU‐13B/P anti‐G suit (STD)
Study: 11346005
Drug: Advanced Technology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced Technology Anti‐G Suit (ATAGS)
Study: 9741373
Drug: Nose mask
Normalized name: WITCH HAZEL 0.01 g in 100 g TOPICAL LIQUID [Charcoal Nose Mask Blackhead Remover]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nose mask CPAP therapy
Study: 9741373
Drug: Face mask
Normalized name: CVS Face Masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face mask CPAP therapy
Study: 9741373
Drug: Nose mask
Normalized name: WITCH HAZEL 0.01 g in 100 g TOPICAL LIQUID [Charcoal Nose Mask Blackhead Remover]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nose mask CPAP therapy for SAHS/U3P
Study: 9741373
Drug: Face mask
Normalized name: CVS Face Masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face mask CPAP therapy for SAHS/U3P
Study: 3127710
Drug: Electroencephalographic class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroencephalographic class 4 (abnormal before treatment and unchanged before withdrawal)
Study: 1098526
Drug: Albuterol aerosol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol aerosol
Study: 17972380
Drug: Beta-blockers (betaB)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (betaB)
Study: 17972380
Drug: Angiotensin-renin system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-renin system blockers (ARSB)
Study: 12494116
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors (ACEI)
Study: 8562538
Drug: 0.5% aldose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% aldose reductase inhibitor (CT-112)
Study: 327814
Drug: Fenoterol (prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (prophylactic administration)
Study: 31431411
Drug: IIV4-HD (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV4-HD (high-dose quadrivalent influenza vaccine)
Study: 28532660
Drug: micro-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: micro-dose recombinant HCG
Study: 11132533
Drug: IFN alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha 6 MU tiw plus Ribavirin 14 mg/kg/day for 12 weeks
Study: 9309491
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluoxetine and selegiline with physostigmine
Study: 3565811
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium chloride (2.5 mg/kg in children; 4, 8, 12 mg/kg in dogs)
Study: 3565811
Drug: Calcium gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium gluconate (7.5 mg/kg in children; 14, 28, 42 mg/kg in dogs)
Study: 31017496
Drug: Intralesional verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional verapamil alone (2.5mg/ml)
Study: 31017496
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pulsed dye laser (PDL) and intralesional verapamil (2.5mg/ml)
Study: 30355464
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care and radiotherapy (daily schedule: 55 Gy in 20 fractions over 4 weeks; weekly schedule: 36 Gy in six fractions over 6 weeks)
Study: 17850607
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus adjunctive CHX chip placement
Study: 17850607
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus adjunctive systemic amoxicillin/metronidazole
Study: 11902611
Drug: Anti-adhesive enamel
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-adhesive enamel coating applied to buccal surfaces of teeth in one quadrant
Study: 7802306
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg immediately and droperidol 0.16 mg with each PCA dose (Group 1)
Study: 7802306
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg immediately (Group 2)
Study: 7802306
Drug: Droperidol 0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.16 mg with each PCA dose (Group 3)
Study: 2148245
Drug: Large doses
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large doses of MPA (Depo-Provera)
Study: 7053117
Drug: bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.25% after interruption of local anaesthetic infusion
Study: 28125821
Drug: MMC/5‐FU vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMC/5‐FU vs. no chemotherapy (necrosis present)
Study: 28125821
Drug: MMC/5‐FU vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMC/5‐FU vs. no chemotherapy (necrosis absent)
Study: 23685099
Drug: Automated intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated intermittent bolus (5 mL every 30 min with 0.1 mL/hr basal rate)
Study: 23685099
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (10.1 mL/hr)
Study: 21509750
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy plus standard care
Study: 10446101
Drug: Bethanechol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol (5 mg subcutaneously)
Study: 10446101
Drug: Atropine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.6 mg then 0.25 mg/hour intravenously)
Study: 28849329
Drug: Lubiprostone 24
Normalized name: LUBIPROSTONE 24MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone 24 mcg BID (CIC)
Study: 28849329
Drug: Lubiprostone 24
Normalized name: LUBIPROSTONE 24MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone 24 mcg BID (OIC)
Study: 28849329
Drug: Lubiprostone 8
Normalized name: LUBIPROSTONE 8MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone 8 mcg BID (IBS-C)
Study: 15793171
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (PC) program
Study: 11978650
Drug: Locally administered
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locally administered insulin
Study: 9579501
Drug: Propofol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with abrupt discontinuation (group 1A)
Study: 9579501
Drug: Propofol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with abrupt discontinuation (group 2A)
Study: 9579501
Drug: Propofol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with descending concentrations (group 1B)
Study: 9579501
Drug: Propofol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with descending concentrations (group 2B)
Study: 2482536
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b (Introna) 3 MU, 3 times weekly subcutaneously for 36 weeks
Study: 320913
Drug: 5% solution
Normalized name: Introl 75% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% solution of metaproterenol, 10 whiffs (1.5 mg) q.i.d.
Study: 320913
Drug: 0.5% isoproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% isoproterenol solution
Study: 23705968
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity training (HIT) intervention - 3 weekly exercise sessions over 7 weeks, consisting of 4 to 6 repeats of maximal sprint running with 30 s recovery
Study: 21726354
Drug: Hydrocortisone treatment
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone treatment for 3 days
Study: 21726354
Drug: Hydrocortisone treatment
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone treatment for 7 days
Study: 17065118
Drug: Sutter implants
Normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutter implants
Study: 14652361
Drug: Betaine 1.5
Normalized name: COCAMIDOPROPYL BETAINE 1.5 mg in 100 g TOPICAL CREAM [Srripo Amino Acid Facial Cleanser]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine 1.5 g/d
Study: 14652361
Drug: Betaine 3
Normalized name: betaine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine 3 g/d
Study: 14652361
Drug: Betaine 6
Normalized name: betaine 648 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine 6 g/d
Study: 11247402
Drug: Holter ECG
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Holter ECG monitoring in patients with glucose metabolism disturbances
Study: 11247402
Drug: Holter ECG
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Holter ECG monitoring in patients without glucose metabolism disturbances
Study: 30284674
Drug: Ileocolonic release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ileocolonic release peppermint oil (IC-PO) 182 mg
Study: 30284674
Drug: Small intestinal
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small intestinal release peppermint oil (SI-PO) 182 mg
Study: 26679155
Drug: Monitoring cerebral
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring cerebral oxygenation by near‐infrared spectroscopy (NIRS) combined with an evidence‐based treatment guideline
Study: 26679155
Drug: No NIRS
Approvals — FDA: no, EMA: no, PMDA: no
Description: No NIRS data and treatment as usual
Study: 22278623
Drug: Benidipine +
Normalized name: manidipine
DrugBank: Manidipine (DB09238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine + β-blocker
Study: 18983246
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment during pregnancy
Study: 18983246
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment during pregnancy
Study: 10340686
Drug: Typical antipsychotic
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical antipsychotic agents
Study: 9219699
Drug: TNFR:Fc 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFR:Fc 16 mg/m²
Study: 2890459
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg with food
Study: 2890459
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg with Gelusil
Study: 2890459
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg with activated charcoal
Study: 2890459
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg with propantheline
Study: 27464467
Drug: Active e-cigarette
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active e-cigarette smoking (smoked a pre-determined number of puffs within 30-min using a liquid with 11 ng/ml nicotine)
Study: 23299877
Drug: Overall gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall gel use
Study: 12660312
Drug: Ayahuasca (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (0.6 and 0.85 mg of DMT/kg of body weight)
Study: 12660312
Drug: Ayahuasca (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (high dose)
Study: 12660312
Drug: Ayahuasca (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (low and high doses)
Study: 8862490
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist and menotropin therapy
Study: 1640854
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion (EPI) at 25 ng/kg/min for 5.5 hours after a basal overnight insulin infusion (12 mU/kg/h)
Study: 8853469
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion (EPI)
Study: 18706202
Drug: 3-week group
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week group (cisplatin 75 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1 and 8 of a 21-day cycle)
Study: 18706202
Drug: 4-week group
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week group (cisplatin 75 mg/m² on day 1 plus gemcitabine 1000 mg/m² on days 1, 8 and 15 of a 28-day cycle)
Study: 12946549
Drug: Cyclosporine Capsule
Normalized name: Cyclosporine Capsules
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine Capsule Satisfaction Survey
Study: 10701814
Drug: Blood cadmium
Normalized name: cadmium
DrugBank: Cadmium (DB14085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood cadmium concentration (B-Cd) and urinary cadmium excretion (U-Cd) measurements
Study: 8443032
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN; 20 mg orally)
Study: 29749032
Drug: Postprandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postprandial insulin aspart regimen
Study: 29749032
Drug: Preprandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preprandial insulin aspart regimen
Study: 27468086
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) including aspirin plus clopidogrel 75 mg/d or prasugrel 10 mg/d (5 mg/d for those <60 kg or age ≥75 years)
Study: 24334689
Drug: CC‐JEV (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC‐JEV (17 μg per dose)
Study: 24334689
Drug: CC‐JEV (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC‐JEV (4 μg per dose)
Study: 24334689
Drug: CC‐JEV (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC‐JEV (8 μg per dose)
Study: 24334689
Drug: MB‐JEV (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: MB‐JEV (17 μg per dose)
Study: 20536495
Drug: Gliclazide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (up to 320 mg/day)
Study: 18692876
Drug: Celecoxib, 100
Normalized name: Celecoxib, 100 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib, 100 mg at 9 pm for 1 month
Study: 16002805
Drug: 4.1 mg
Normalized name: menthol 4.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.1 mg lutein (n = 8)
Study: 16002805
Drug: 20.5 mg
Normalized name: acetaminophen 320.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20.5 mg lutein (n = 8)
Study: 10369152
Drug: Psychoeducational medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational medication management training
Study: 1781976
Drug: Cognition enhancers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognition enhancers (CEs) - piracetam, acetyl‐L‐carnitine, nimodipine (NIM)
Study: 6783205
Drug: Tea consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea consumption (2 litres of tea daily, 4 bags of 2 g Assam/Ceylon tea per litre, steeped for 5 minutes)
Study: 6783205
Drug: Water consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water consumption (2 litres of tap water daily)
Study: 31575299
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy plus usual care
Study: 28004200
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin infusion
Study: 26108255
Drug: Oxycodone DETERx®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone DETERx® (intact)
Study: 26108255
Drug: Oxycodone DETERx®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone DETERx® (crushed)
Study: 26108255
Drug: IR oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR oxycodone (crushed)
Study: 23293276
Drug: Intraperitoneal nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal nebulization of ropivacaine 1% (3 ml) before surgical dissection and normal saline 3 ml at the end of surgery (preoperative nebulization group)
Study: 23293276
Drug: Intraperitoneal nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal nebulization of normal saline 3 ml before surgical dissection and ropivacaine 1% (3 ml) at the end of surgery (postoperative nebulization group)
Study: 23293276
Drug: Intraperitoneal nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal nebulization of normal saline 3 ml before surgical dissection and at the end of surgery (placebo group)
Study: 19376305
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy for 6 months
Study: 19376305
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy for 12 months
Study: 17214931
Drug: Ruyi Dingchuan
Normalized name: BENZALKONIUM CHLORIDE 0.148 g in 100 mL TOPICAL SPRAY [Jingchuang Chonggao Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruyi Dingchuan Pill
Study: 4015075
Drug: Moxalactam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam (4 g intravenously every 12 h)
Study: 4015075
Drug: Temocillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocillin (4 g intravenously every 12 h)
Study: 21313926
Drug: Closed and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed and totally hyaluronan based heparin free coated ECC
Study: 21313926
Drug: Open, totally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open, totally hyaluronan based heparin free coated ECC
Study: 12161496
Drug: Gas chromatography/mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gas chromatography/mass spectrometry method for simultaneous measurement of 15 urinary steroid metabolites
Study: 10341861
Drug: rIFN-alpha +
Normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-alpha + iodine (10 drops SSKI, approximately 350 mg iodine daily)
Study: 10341861
Drug: Iodine alone
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine alone (10 drops SSKI, approximately 350 mg iodine daily)
Study: 6997111
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release form of amitriptyline (Lentizol) 50 mg (doubled after 1 week)
Study: 6997111
Drug: Dothiepin (Prothiaden)
Normalized name: dothiepin
DrugBank: Dosulepin (DB09167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin (Prothiaden) 75 mg (doubled after 1 week)
Study: 28391657
Drug: apremilast 20
Normalized name: apremilast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apremilast 20 mg b.i.d.
Study: 22958974
Drug: Glycerol phenylbutyrate
Normalized name: Glycerol Phenylbutyrate
DrugBank: Glycerol phenylbutyrate (DB08909)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Glycerol phenylbutyrate (1.5 to 31.8 g/day)
Study: 22958974
Drug: Sodium phenylbutyrate
Normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium phenylbutyrate (1.3 to 31.7 g/day)
Study: 17523342
Drug: Omeprazole (OPZ)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (OPZ) 20 mg/day + AMPC 1500 mg/day + CAM 600 mg/day (OAC)
Study: 17523342
Drug: Lansoprazole (LPZ)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole (LPZ) 30 mg + AMPC 1500 mg/day + CAM 600 mg/day (LAC)
Study: 17523342
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RPZ) 10 mg/day + AMPC 1500 mg/day + CAM 600 mg/day (RAC)